Avadel Pharma (AVDL) Reports Q1 EPS of $0.26, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Avadel Pharmaceuticals Reports First Quarter 2017 Results
May 9, 2017 7:30 AM EDTDUBLIN, Ireland, May 09, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ: AVDL) today announced its financial results for the first quarter of 2017.
Highlights Include:
Total revenues for the first quarter 2017 were $52.5 million, compared to $43.1 million in the fourth quarter 2016 and $36.2 million in the first quarter 2016. GAAP net income for the first quarter 2017 was $25.4 million, or $0.59 per diluted share, compared to GAAP net income of $4.7 million, or $0.11 per diluted share, in the fourth quarter 2016 and a GAAP net loss of $6.1 million, or $0.15 per diluted... More